Literature DB >> 2164440

Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line.

K Miyazaki1, H Takaku, M Umeda, T Fujita, W D Huang, T Kimura, J Yamashita, T Horio.   

Abstract

Two kinds of growth-inhibitory substances were found in culture of a Rous sarcoma virus-transformed rat liver cell line, RSV-BRL. The two substances were purified from the serum-free culture medium and identified as transforming growth factor beta 1 and Mycoplasma-derived arginine deiminase (EC 3.5.3.6), respectively. The arginine deiminase was an acid-labile but dithiothreitol-resistant protein with a molecular weight of 45,000 and pI 4.7. Its Km value for L-arginine was 0.3 mM, which is about 30 times lower than that of bovine liver arginase. It was stable and active under culture conditions. When added into cultures, the arginine deiminase inhibited the growth of various human cancer cell lines at a dose of 5 ng/ml or higher by depleting L-arginine in the culture media. This effective dose was about 1000 times lower than that of bovine liver arginase. These results suggested the possibility of chemotherapeutic use of arginine deiminase for human cancers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164440

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

Review 1.  Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

Authors:  N Savaraj; M You; C Wu; M Wangpaichitr; M T Kuo; L G Feun
Journal:  Curr Mol Med       Date:  2010-06       Impact factor: 2.222

2.  Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts.

Authors:  Evan S Glazer; Everett M Stone; Cihui Zhu; Katherine L Massey; Amir N Hamir; Steven A Curley
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

3.  Argininosuccinate synthase: at the center of arginine metabolism.

Authors:  Ricci J Haines; Laura C Pendleton; Duane C Eichler
Journal:  Int J Biochem Mol Biol       Date:  2011

Review 4.  Arginine dependence of tumor cells: targeting a chink in cancer's armor.

Authors:  M D Patil; J Bhaumik; S Babykutty; U C Banerjee; D Fukumura
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

5.  Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.

Authors:  Hua Yang; Ming Lin; Fuxia Xiong; Yu Yang; Xiu Nie; Michael A McNutt; Rouli Zhou
Journal:  Surg Today       Date:  2011-05-28       Impact factor: 2.549

Review 6.  Arginine catabolism, liver extracts and cancer.

Authors:  Denys N Wheatley; Elaine Campbell
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

7.  Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.

Authors:  Randie H Kim; Jodi M Coates; Tawnya L Bowles; Gregory P McNerney; Julie Sutcliffe; Jae U Jung; Regina Gandour-Edwards; Frank Y S Chuang; Richard J Bold; Hsing-Jien Kung
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 8.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

Review 9.  Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.

Authors:  Macus Tien Kuo; Niramol Savaraj; Lynn G Feun
Journal:  Oncotarget       Date:  2010-08

10.  Elevation of endothelin biosynthesis in human endothelial cells with mycoplasma infection.

Authors:  M Matsui; M Kobayashi; Y Mitsup
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-12       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.